A comparative study on micelles, liposomes and solid lipid nanoparticles for paclitaxel delivery.


Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
25 Jan 2023
Historique:
received: 18 08 2022
revised: 13 11 2022
accepted: 27 11 2022
pubmed: 5 12 2022
medline: 14 1 2023
entrez: 4 12 2022
Statut: ppublish

Résumé

The purpose of this work was to compare the in vitro and in vivo characteristics of LDV-targeted lipid-based micelles, liposomes and solid lipid nanoparticles (SLN) to provide further insights into their therapeutic potential for clinical development. Micelles, liposomes and SLN were prepared using LDV peptide amphiphiles and palmitic acid-derived lipids using solvent evaporation, thin-film hydration and microfluidic mixing respectively. Nanocarriers were characterized for their physicochemical properties, paclitaxel loading efficiency, in vitro release behavior, stability in biological media as well as in vivo antitumor efficacy in melanoma xenograft model. TEM and DLS results confirmed the presence of paclitaxel-loaded nanosized micelles (6 to 12 nm), liposomes (123.31 ± 5.87 nm) and SLN (80.53 ± 5.37 nm). SLN demonstrated the slowest paclitaxel release rate and the highest stability in biological media compared to micelles and liposomes. Paclitaxel-loaded SLN demonstrated a statistically significant delay in tumor growth compared to mice treated with paclitaxel-loaded liposomes and paclitaxel-loaded micelles (p < 0.05). The results obtained in this study indicate the potential of SLN as drug delivery vehicles for anticancer therapy.

Identifiants

pubmed: 36464111
pii: S0378-5173(22)01019-5
doi: 10.1016/j.ijpharm.2022.122464
pii:
doi:

Substances chimiques

Lipid Nanoparticles 0
Liposomes 0
Paclitaxel P88XT4IS4D
Micelles 0
Drug Carriers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

122464

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Shradha Dattani (S)

University of the Pacific, Stockton, CA, USA.

Xiaoling Li (X)

University of the Pacific, Stockton, CA, USA.

Charina Lampa (C)

Inhalation Product Development, PT&D AstraZeneca LLC, South San Francisco, CA, USA.

David Lechuga-Ballesteros (D)

Inhalation Product Development, PT&D AstraZeneca LLC, South San Francisco, CA, USA.

Amanda Barriscale (A)

Inhalation Product Development, PT&D AstraZeneca LLC, South San Francisco, CA, USA.

Behzad Damadzadeh (B)

Inhalation Product Development, PT&D AstraZeneca LLC, South San Francisco, CA, USA.

Bhaskara R Jasti (BR)

University of the Pacific, Stockton, CA, USA. Electronic address: bjasti@pacific.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH